FURTHER encouraging results around migraine therapy have been demonstrated in two separate UK clinical trials.
Antibody erenumab made by Novartis, was trialled on 955 patients with episodic migraine (PD Fri) while another, fremanezumab made by Teva pharmaceuticals, was trialled on 1,130 patients with chronic migraine, according to a BBC report.
Research has shown a chemical in the brain - calcitonin gene-related peptide or CGRP - is involved in both pain and sensitivity to sound and light in migraine.
Four drug companies are now racing to develop antibodies that neutralise CGRP either by sticking to CGRP, or by blocking the part of a brain cell with which it interacts.
The above article was sent to subscribers in Pharmacy Daily's issue from 04 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 04 Dec 17
